Serotonin adipate in intensive therapy of patients with severe COVID-19

In this article, we discuss the history of discovery of serotonin deficiency and therapy for it. We described the experience of using serotonin adipate as a part of comprehensive intensive therapy for severe COVID-19. We also describe treatment outcome of a 52-year-old female patient treated in the intensive care unit of the Clinical Hospital for Infectious Diseases No 2 with a diagnosis of community-acquired polysegmental pneumonia, confirmed COVID-19, and functional intestinal obstruction. Her condition was complicated by infectious and toxic dilated cardiomyopathy of mixed origin (caused by both coronavirus itself and substrates of enterogenic endotoxicosis) and hemodynamic instability manifesting itself with arterial hypotension that required micro-injections of norepinephrine. The comprehensive treatment aimed to eliminate growing endotoxicosis caused by intestinal insufficiency, so we had to adjust her intensive therapy by adding serotonin adipate to the treatment scheme. Good treatment outcome of this patient was ensured by an improved strategy of intensive therapy that included a drug restoring and stimulating functions of smooth muscles. Later, the patient was transferred to the specialized department, recovered, and discharged from hospital. Key words: intensive care, COVID-19, serotonin adipate